These results indicate that CXCL13+ T cells are associated with a favorable response to ICB therapy, suggesting that increasing CXCL13+ T cell populations could enhance ICB therapy efficacy in cancer immunotherapy. This evidence concerns the gene CXCL13 and cancer.